News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opko Health, Inc. Granted Patent From U.S. Patent & Trademark Office For RAYALDEE


7/22/2014 10:06:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced that the United States Patent and Trademark Office granted OPKO a patent covering RAYALDEE™, the Company’s product to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The new patent (US Pat. No. 8,778,373) provides OPKO with additional intellectual property protection covering controlled release administration of a vitamin D compound. OPKO is on schedule to announce top-line results from the first pivotal phase 3 trial for RAYALDEE in the third quarter of 2014 and file a New Drug Application (NDA) with the FDA in the first quarter of 2015.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES